11-Ketotestosterone is the predominant active androgen in prostate cancer patients after castration

BACKGROUND: Continued androgen receptor (AR) signaling constitutes a key target for treatment in metastatic castration-resistant prostate cancer (CRPC). Studies have identified 11-ketotestosterone (11KT) as a potent AR agonist, but it is unknown if 11KT is present at physiologically relevant concent...

詳細記述

保存先:
書誌詳細
出版年:JCI Insight
主要な著者: Snaterse, Gido, van Dessel, Lisanne F., van Riet, Job, Taylor, Angela E., van der Vlugt-Daane, Michelle, Hamberg, Paul, de Wit, Ronald, Visser, Jenny A., Arlt, Wiebke, Lolkema, Martijn P., Hofland, Johannes
フォーマット: Artigo
言語:Inglês
出版事項: American Society for Clinical Investigation 2021
主題:
Clinical Medicine
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC8262344/
https://ncbi.nlm.nih.gov/pubmed/33974560
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/jci.insight.148507
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料